SLC6A3 and neuroendocrine neoplasm: The genetic amplification of DAT/SLC6A3 was frequently found in 14% of castration-resistant prostate cancer (CRPC, known as neuroendocrine tumor), 12% of pancreatic cancer, 13% of lung squamous cell carcinoma (SCC), 11% of lung adenocarcinoma, 12% of esophagus cancer, 12% of sarcoma, 9% of bladder cancer, and 8% of ovarian cancer (Figure 7A, Figure S7).